GLP-1-induced gastroparesis
Adverse events on the FDA labels, with the canonical evidence anchors.
Definition
Delayed gastric emptying severe enough to cause persistent nausea, vomiting, or food retention after a GLP-1 dose. A 2023 JAMA case-control study (PMID 37335445) found GLP-1 use associated with a 3.7-fold increased risk of clinically diagnosed gastroparesis vs bupropion-naltrexone. Risk rises with higher doses, faster titration, and pre-existing diabetic autonomic neuropathy. Symptoms usually resolve within 4-8 weeks of dose reduction or discontinuation.
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Side effects
Looking for more depth?
- Side-effect timeline tool
- Browse the full GLP-1 glossary (61 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers